Complete Story
 

November 4: Pharmacist Training Program for Long-Acting Injectables

OPA Office: 2674 Federated Blvd, Columbus

OPA is pleased to announce its live training program on Thursday, November 4, 2021 for pharmacists who plan to administer the following long-acting or extended-release dangerous drugs permitted by Ohio Revised Code 4729.45:

  1. Opioid antagonist used for treatment of drug addiction or alcohol dependence and administered in long-acting or extended-release form;
  2. Antipsychotic drug administered in long-acting or extended-release form;
  3. Hydroxyprogesterone caproate for pregnant women;
  4. Medroxyprogesterone acetate for non-pregnant women;
  5. Cobalamin.

The live training will be held at the OPA office in Columbus, and includes sessions on implementing administration of antipsychotic medications in pharmacy practice; naltrexone administration and the required testing; and sterile preparation and administration technique for administering these medications. The administration technique session will include SC injections in the upper arm and abdomen, and IM injections in the deltoid and gluteal muscles. Completion of the home-study lessons on LAI antipsychotics, naltrexone, and buprenorphine is required before attending the live session.

Home-study lessons on each of the five categories of dangerous drugs are available for purchase on the OPA website. These lessons meet the training requirements in Ohio Administrative Code (OAC) 4729-5-40(K)(2). Pharmacists who have met the training requirements for administration of immunizations (OAC 4729-5-36) are not required to complete additional training in administration technique, if their previous training included the same injection techniques necessary to administer the dangerous drug.

Seating is limited.

Click HERE to Register

NOTE: Non-member registration will open on September 15, 2021.

Brochure for LAI Training Program for Long-Acting Injectables

If you are unable to attend the next program but are interested in attending a future program, please complete the following form:


Long-Acting Injectables Program Interest Form

Printer-Friendly Version